A new publication involving buserelin was released on July 7, 2026. The study, titled "Optimizing ovulation synchronization in Holstein heifers: implementing a half-dose GnRH analogue (Buserelin Acetate) in a nanofabricated form within the ovsynch protocol to enhance the ovarian activity and reproductive performance outcomes," appeared in Frontiers in Veterinary Science.
The publication is listed under PubMed ID 42483712. It examines the use of a half-dose, nanofabricated form of Buserelin Acetate, a GnRH analogue, within the Ovsynch protocol in Holstein heifers. No specific findings, results, or outcome data from the study are included in this brief, as only the publication's title, journal, and date have been provided.
Buserelin is an approved compound. This report reflects only the existence and bibliographic details of the newly published study, not an assessment of its conclusions. Readers interested in the broader context of buserelin, including its approved uses and background, can consult the compound overview for additional information.